Repligen
RGEN
Repligen (RGEN) - Cash on Hand
Cash on Hand as of December 2023 : $0.75 B
According to Repligen
's latest financial reports the company has $0.75 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Repligen - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.75 B | 20.45% |
| 2022-12-31 | $0.62 B | 3.3% |
| 2021-12-31 | $0.60 B | -15.82% |
| 2020-12-31 | $0.71 B | 35.75% |
| 2019-12-31 | $0.52 B | 172.62% |
| 2018-12-31 | $0.19 B | 11.55% |
| 2017-12-31 | $0.17 B | 22.56% |
| 2016-12-31 | $0.14 B | 97.54% |
| 2015-12-31 | $71.77 M | 22.79% |
| 2014-12-31 | $58.45 M | -5.14% |
| 2013-12-31 | $61.62 M | 53.85% |
| 2012-12-31 | $40.05 M | |
| 2011-03-31 | $49.62 M | -6.61% |
| 2010-03-31 | $53.13 M | 8.75% |
| 2009-03-31 | $48.85 M | -1.86% |
| 2008-03-31 | $49.78 M | 120.02% |
| 2007-03-31 | $22.62 M | 19.87% |
| 2006-03-31 | $18.87 M | 9.68% |
| 2005-03-31 | $17.2 M | 23.33% |
| 2004-03-31 | $13.95 M | -10.12% |
| 2003-03-31 | $15.52 M | -25.5% |
| 2002-03-31 | $20.83 M | -12.94% |
| 2001-03-31 | $23.93 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $12.69 B | 1,589.02% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | $8.07 B | 975.04% | 🇺🇸 USA |
 General Electric GE | $22.67 B | 2,917.74% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $12.28 B | 1,534.45% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $81 M | -89.22% | 🇺🇸 USA |
 Novavax NVAX | $0.56 B | -24.33% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $1.03 B | 37.30% | 🇺🇸 USA |
 Bio-Techne TECH | $0.13 B | -81.94% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.07 B | 42.92% | 🇺🇸 USA |
 Charles River Laboratories
CRL | $0.27 B | -63.16% | 🇺🇸 USA |